AAO research
Editorial boards, neuroscience contributions, scholarly articles, and corroborating citations supported this researcher’s successful EB-1A appeal and petition approval.
Decision snapshot
Decision detail | Source-backed value |
|---|---|
Decision ID | AUG172005_01B2203 |
Disposition stated in the source | Appeal sustained; petition approved. |
Source location |
The AAO accepted three categories
The biomedical researcher was an NIH visiting postdoctoral research fellow when the petition was filed. Editorial-board service supported judging. The AAO also accepted original contributions of major significance and scholarly articles.
Source: AUG172005_01B2203 page 2; AUG172005_01B2203 page 3; AUG172005_01B2203 page 5.
Scientific explanations and citations corroborated significance
Detailed expert letters explained neurogranin’s role in signaling pathways related to learning and memory and described a radial-arm maze test used in drug research. Citation indices showed an aggregate 144 citations, which the AAO found bolstered the experts’ significance assessments. The decision did not create a universal 144-citation standard or claim a treatment had already been developed.
Source: AUG172005_01B2203 page 3; AUG172005_01B2203 page 4.
The total evidence supported approval
The AAO found influence beyond the researcher’s own institutions and an overall pattern of sustained national and international acclaim, along with continued work and prospective benefit. It sustained the appeal and approved the petition. This 2005 decision predates Kazarian; it should not be rewritten as though it used the later expressly labeled two-stage procedure.
Source: AUG172005_01B2203 page 4; AUG172005_01B2203 page 5.
Current framework and related reading
The decisions above are non-precedent assessments of particular records. Historical reasoning is identified as historical; consult current guidance for the present framework.